FDA approves Zydus' trial of Usnoflast for ALS treatment
3 days ago · Also known as ZYIL1, Usnoflast has been explored in various pre-clinical studies for neuroinflammation and other conditions. The company has also secured orphan drug status …
Zydus announces USFDA Orphan Drug Designation for Usnoflast …
13 hours ago · Usnoflast (ZYIL1) has been studied in various pre-clinical models, including Parkinson’s disease and Multiple Sclerosis. Zydus has previously completed a Phase 2(a) …
• Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus Research Centre, the R&D arm of Zydus Lifesciences Ltd. • Usnoflast is under clinical development in 4 …
Zydus receives USFDA Orphan Drug Designation for Usnoflast to …
22 hours ago · Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for treating amyotrophic lateral sclerosis (ALS), a …
Zydus Lifesciences concludes subject enrolment in ALS trial
May 24, 2024 · Zydus Lifesciences has completed enrolment in the Phase II clinical trial of Usnoflast (ZYIL1) to treat amyotrophic lateral sclerosis (ALS).
Zydus, a leading discovery-based, global pharmaceutical company, announced today that it has completed enrolment of its Phase II clinical study of NLRP3 inhibitor ‘Usnoflast (ZYIL1)’ in …
Zydus Lifesciences Receives Approval from USFDA to Conduct …
5 days ago · Usnoflast has been studied in several pre-clinical models of neuroinflammation, Parkinson's disease, Inflammatory Bowel Disease (IBD) and Multiple Sclerosis (MS). The …
ZydusLifesciencesannouncescompletion of Phase II(a) clinical trial …
Sep 10, 2024 · Usnoflast (ZYIL1) is a novel, oral small molecule NLRP3 inhibitor. Studies have demonstrated that Usnoflast is highly potent in human whole blood assay and can suppress …
Zydus Lifesciences announces WHO approval for NLRP3 inhibitor Usnoflast
Apr 1, 2024 · Usnoflast (ZYIL1) is an innovative oral small molecule NLRP3 inhibitor, showcasing high potency in human whole blood assays and the ability to suppress inflammation caused by …
Zydus Lifesciences completes Phase II (a) clinical trial of Usnoflast ...
Sep 12, 2024 · Zydus’s Usnoflast, also known as ZYIL1, is the first NLRP3 inhibitor to demonstrate proof-of-concept in ALS patients. The 12-week randomized, double-blind, …
- Some results have been removed